King Pharmaceuticals KG Payments for (Proceeds from) Loans Receivable

Payments for (Proceeds from) Loans Receivable at other companies

W.R. BerkleyWRB

——

Kearny FinancialKRNY

——

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Operating cash flow-$15.1M-1,628%

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Net margin131.5%—

Return on equity90.8%—

Debt / equity1.5×—

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForProceedsFromLoansReceivable.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is King Pharmaceuticals's payments for (proceeds from) loans receivable?: King Pharmaceuticals (KG) reported payments for (proceeds from) loans receivable of -$9.48M in Q1 2026.